Trejo L.J., Titone S., Spencer K.M., Ruigt G.S.F. , Ereshefsky L. , Rosipal R. , English B.A. , Donello J.E., Killion B.
Quantitative electroencephalograms and event-related potentials as biomarkers in central nervous system drug development
Frontiers in Pharmacology, 17:1982607, 2026. doi:10.3389/fphar.2026.1982607.
Quantitative electroencephalography and event-related potentials are scalable
translational biomarkers of the pharmacodynamic effects of drugs acting in the
central nervous system. This review synthesizes evidence for resting-state
quantitative electroencephalography, sensory-evoked responses, and
endogenous event-related potentials across major central nervous system drug
classes, including antidepressants, antiseizure medications, antipsychotics,
cannabinoids, cholinergic modulators, N-methyl-D-aspartate (NMDA) receptor
modulators, psychedelics, sedatives, stimulants, and selected mixed-mechanism
agents. Across classes, drug effects are most interpretable when spectral power
is separated into periodic and aperiodic activity, and when resting-state
measures are integrated with event-related biomarkers such as mismatch
negativity, auditory steady-state response, sensory gating, and P300. The
evidence supports several mechanistic principles: γ- and δ-subunit-containing
GABAA modulation generate distinct electrophysiological profiles; NMDA receptor
antagonism dissociates spontaneous from evoked gamma band activity;
cholinergic tone produces bidirectional and pharmacologically transparent effects
on cortical desynchronization and sensory gating; and catecholaminergic,
serotonergic, sedative, and antiseizure agents converge on several non-specific
band-power changes. These convergences limit the interpretability of biomarkers
and support the use of prespecified multi-feature panels that combine spectral,
aperiodic, connectivity, and event-related measures. We conclude with practical
recommendations for early-phase clinical trials, including time-matched
baselines, control of vigilance and eye condition, pharmacokinetic-
pharmacodynamic sampling, standardized acquisition, and statistical analysis
plans suitable for biomarker qualification.